Comparative Pharmacology
Head-to-head clinical analysis: ARMODAFINIL versus FOCALIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMODAFINIL versus FOCALIN XR.
ARMODAFINIL vs FOCALIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armodafinil is a wakefulness-promoting agent. Its mechanism is unclear but may involve inhibition of dopamine reuptake, leading to increased extracellular dopamine levels. It also affects orexin, histamine, norepinephrine, and GABA pathways.
Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.
Adults: 150-250 mg orally once daily in the morning for narcolepsy or obstructive sleep apnea; 200-400 mg orally once daily for shift work disorder.
Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.
None Documented
None Documented
Clinical Note
moderateArmodafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Cyclosporine
"The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil."
Clinical Note
moderateCyclophosphamide + Armodafinil
12–15 hours (terminal) in adults; longer in hepatic impairment (e.g., 20–30% increase with cirrhosis).
Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR)
Renal: ~80% as metabolites (major: armodafinil acid, minor: modafinil sulfone); fecal: <1% unchanged; biliary: negligible.
Renal (approximately 90% as unchanged drug and metabolites)
Category C
Category C
CNS Stimulant
CNS Stimulant
"The metabolism of Armodafinil can be decreased when combined with Cyclophosphamide."